Application of 10-hydroxydecenoic acid preparation in preparation of medicine for treating Alzheimer disease

By using co-solvents such as meglumine in 10-hydroxydecenoic acid preparations, the water solubility and efficacy are improved, and the problem of being difficult to dissolve in water is solved, which significantly improves the therapeutic effect of Alzheimer's disease and reduces the risk of side effects.

CN118948822APending Publication Date: 2024-11-15CHINA PHARM UNIV +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202311143274.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-09-05
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing 10-hydroxydecenoic acid is difficult to dissolve in water, resulting in poor solubility in drug preparations, making it difficult to effectively exert the efficacy of anti-Alzheimer's disease, and the existing therapeutic drugs have limited effect on severe cases and exist. side effect.

Method used

Using megamine as a co-solvent, combined with sodium thiosulfate and purified water, prepare injections of 10-hydroxydecenoic acid, oral solution agents and dispersed tablets, improve its solubility and efficacy in aqueous solution, and use orally The dosing method significantly improves the level of central neurotransmitters.

Benefits of technology

Significantly improves the dissolution of 10-hydroxydecenoic acid and its efficacy against Alzheimer's disease, increases the exposure level in the central nervous system, provides better therapeutic effects and safety, and is simple in technology and suitable for large Large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948822A_ABST
    Figure CN118948822A_ABST
Patent Text Reader

Abstract

The invention provides a common tablet, a dispersible tablet, an oral solution and an injection of 10-hydroxydecenoic acid, which are used for treating or preventing Alzheimer's disease. The 10-hydroxydecenoic acid preparation provided by the invention has a relatively good treatment effect on rat models with various Alzheimer diseases, and the levels of transmitters such as dopamine and acetylcholine in a plurality of tissues of a central pivot are obviously improved. The 10-hydroxydecenoic acid preparation is stable, takes effect quickly, is simple in preparation process and is suitable for large-scale production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine, and particularly relates to application of a 10-hydroxydecenoic acid preparation in treating Alzheimer's disease. Background Art

[0002] Royal jelly acid is also called 10-hydroxydecenoic acid (10-HDA, C 10 H 18 O3), comes from royal jelly, which is a substance secreted by the glands in the head of the bees in the honey bee colony. Royal jelly contains 62.5% to 70% water, and the rest is protein, sugar, fatty acids, etc. The main active substances in royal jelly are protein and fatty acids.

[0003] 10-Hydroxydecenoic acid is a natural unsaturated fatty acid and an important indicator for measuring the quality of royal jelly and distinguishing its authenticity. 10-Hydroxydecenoic acid accounts for 50% of the total fatty acids in royal jelly and about 1.8% of the dry weight of royal jelly. 10-Hydroxydecenoic acid is a white crystal at room temperature, with stable properties, insoluble in water, soluble in methanol, ethanol, chloroform, slightly soluble in acetone, and has a melting point of 64°C.

[0004] Generally, 10-hydroxydecenoic acid can be directly isolated from royal jelly or synthesized artificially.

[0005]

[0006] Alzheimer's disease (AD) is a systemic neurodegenerative syndrome whose incidence increases with age. The main clinical features are decreased central cognitive function, mental and movement disorders, and the course of the disease is slow, difficult to detect and irreversible. According to the "2021 World Alzheimer's Report", there were more than 55 million AD patients in the world in 2021. It is estimated that by 2030, this number will reach 78 million. In today's society where the aging population is becoming increasingly serious, AD not only seriously affects the life, health and quality of life of patients, but also brings huge burdens to families and society. It is a global medical and social problem.

[0007] At present, the drugs used clinically to treat AD, except for memantine which is an N-methyl-D-aspartate receptor blocker, donepezil, galantamine, and rivastigmine are all cholinesterase inhibitors. Most of these marketed drugs are only suitable for the treatment of mild and moderate AD and have limited effects. In July 2023, Leqembi, a monoclonal antibody targeting Aβ protein jointly developed by Biogen and Eisai, was approved by the U.S. Food and Drug Administration as a new anti-AD drug. However, its clinical trial results showed that some patients experienced side effects such as cerebral edema and cerebral hemorrhage. Faced with the severe situation of lack of drugs for the prevention and treatment of AD, there is an urgent need to research and discover safe and effective drugs for the prevention and treatment of AD.

[0008] CN104415025B discloses a composition for delaying the progression of degenerative diseases, including royal jelly acid or royal jelly acid derivatives, γ-aminobutyric acid or γ-aminobutyric acid derivatives; CN 104415066A discloses a composition for treating degenerative diseases, the composition also includes γ-aminobutyric acid or γ-aminobutyric acid derivatives, royal jelly acid or royal jelly acid derivatives, γ-aminobutyric acid or γ-aminobutyric acid derivatives and ginkgo biloba, discloses that the composition can be a tablet, or a capsule, or a liquid, or a powder, discloses that the excipients include a binder and a solvent, the binder is any one of β-cyclodextrin or starch, and the solvent is any one of water and ethanol. However, 10-hydroxydecenoic acid is poorly soluble in water, and ordinary preparations are difficult to exert their efficacy. It is unclear what method to use and how to better exert the anti-AD efficacy of 10-hydroxydecenoic acid. Summary of the invention

[0009] In view of the deficiencies of the prior art, the present invention provides a pharmaceutical composition for treating Alzheimer's disease.

[0010] The technical scheme of the present invention is as follows: a preparation of 10-hydroxydecenoic acid is used for preparing a drug for treating Alzheimer's disease, and the preparation is selected from ordinary tablets, dispersible tablets, oral solutions or injections.

[0011] A 10-hydroxydecenoic acid injection for treating Alzheimer's disease comprises the following components by weight: 0.3-2.4 parts of 10-hydroxydecenoic acid, 1 part of sodium thiosulfate, 1.5-4.0 parts of meglumine and purified water.

[0012] Preferably, the unit preparation of 10-hydroxydecenoic acid injection is 5 mL, containing 10 to 240 mg of 10-hydroxydecenoic acid; more preferably, the unit preparation of 10-hydroxydecenoic acid injection is 5 mL, containing 60 mg to 120 mg of 10-hydroxydecenoic acid.

[0013] A 10-hydroxydecenoic acid oral solution for treating Alzheimer's disease comprises the following components by weight: 0.3-2.4 parts of 10-hydroxydecenoic acid, 1 part of sodium thiosulfate, 1.5-4.0 parts of meglumine and purified water.

[0014] Preferably, the unit preparation of the 10-hydroxydecenoic acid oral solution is 5 mL, containing 10 to 240 mg 10-hydroxydecenoic acid; preferably, the unit preparation of the 10-hydroxydecenoic acid oral solution is 5 mL, containing 60 to 120 mg 10-hydroxydecenoic acid.

[0015] A 10-hydroxydecenoic acid dispersible tablet for treating Alzheimer's disease comprises the following ingredients by weight: 3-24 parts of 10-hydroxydecenoic acid, 10-25 parts of compressible starch, 10-12 parts of microcrystalline cellulose, 8-12 parts of sodium carboxymethyl starch, 10-30 parts of meglumine, 2 parts of sodium thiosulfate, and 0.6 parts of micro-powdered silica gel.

[0016] Preferably, each of the 10-hydroxydecenoic acid dispersible tablets contains 10 mg to 360 mg of 10-hydroxydecenoic acid; more preferably, each of the 10-hydroxydecenoic acid dispersible tablets contains 60 mg to 120 mg of 10-hydroxydecenoic acid.

[0017] A common 10-hydroxydecenoic acid tablet for treating Alzheimer's disease comprises the following ingredients by weight: 3-24 parts of 10-hydroxydecenoic acid, 10-25 parts of corn starch, 10-12 parts of microcrystalline cellulose, 3 parts of povidone, 1 part of sodium thiosulfate, 10-30 parts of meglumine and 0.5 part of micro-powder silica gel.

[0018] Preferably, each ordinary tablet of 10-hydroxydecenoic acid contains 10 mg to 360 mg of 10-hydroxydecenoic acid; preferably, each ordinary tablet of 10-hydroxydecenoic acid contains 60 mg to 120 mg of 10-hydroxydecenoic acid.

[0019] The injection, oral solution, common tablet and dispersible tablet of 10-hydroxydecenoic acid provided by the invention are used for preparing medicine for treating or preventing Alzheimer's disease.

[0020] Beneficial effects of the present invention: The present invention has found that oral administration has obvious efficacy, and the preparation of dispersible tablets is conducive to the dissolution of 10-hydroxydecenoic acid. Moreover, meglumine can not only increase the dissolution of 10-hydroxydecenoic acid in oral solid preparations, produce better anti-AD efficacy, and significantly improve the levels of transmitters such as dopamine and acetylcholine in multiple central tissues, but also significantly increase the dissolution of 10-hydroxydecenoic acid in aqueous solution, and prepare injections or true solutions. The true solution administration has better anti-AD effect than the suspension administration in a non-dissolved state. The 10-hydroxydecenoic acid preparation provided by the present invention is stable, fast-acting, simple in preparation process, and suitable for large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1The efficacy of 10-hydroxydecenoic acid on the AD model induced by aluminum chloride and D-galactose; A: start and end time of modeling, drug administration and AD index test; B: latency on the fifth day of water maze training (positioning navigation experiment); C: number of times of crossing the platform on the sixth day of water maze (spatial exploration experiment); D: number of times of entering the target quadrant on the sixth day of water maze; E: target quadrant movement time on the sixth day of water maze; F: target quadrant movement distance on the sixth day of water maze; H: movement trajectory on the fifth day of water maze training (positioning navigation with platform); I: movement trajectory on the sixth day of water maze (spatial exploration without platform). The low and high doses of 10-hydroxydecenoic acid administered by gavage were 60 mg / kg and 120 mg / kg, respectively. One-way ANOVA analysis was used, *p<0.05, **p<0.01, ***p<0.001. )

[0022] Figure 2 The efficacy of 10-hydroxydecenoic acid on the AD model induced by ibotenic acid; A: start and end time of modeling, drug administration and AD index test; B: latency on the fifth day of water maze training (positioning navigation experiment); C: number of platform crossings on the sixth day of water maze (spatial exploration experiment); D: number of times entering the target quadrant on the sixth day of water maze; E: target quadrant movement time on the sixth day of water maze; F: target quadrant movement distance on the sixth day of water maze; H: movement trajectory on the fifth day of water maze training (positioning navigation with platform); I: movement trajectory on the sixth day of water maze (spatial exploration without platform). 10-hydroxydecenoic acid was dispersed in 0.5% CMC-Na solution to form a suspension (H), or added with meglumine to solubilize and prepare a true solution (R). The dosage was 120 mg / kg, and one-way ANOVA analysis was used, *p<0.05, **p<0.01. )

[0023] Figure 3 The efficacy of 10-hydroxydecenoic acid on scopolamine-induced AD model; A: start and end time of modeling, drug administration and AD index test; B: latency on the fifth day of water maze training (positioning navigation experiment); C: number of platform crossings on the sixth day of water maze (spatial exploration experiment); D: number of times entering the target quadrant on the sixth day of water maze; E: target quadrant movement time on the sixth day of water maze; F: target quadrant movement distance on the sixth day of water maze; H: movement trajectory on the fifth day of water maze training (positioning navigation with platform); I: movement trajectory on the sixth day of water maze (spatial exploration without platform). 10-hydroxydecenoic acid was dispersed in 0.5% CMC-Na solution to form a suspension (H), or added meglumine to solubilize and prepare a true solution (R). The dosage was 120 mg / kg, and one-way ANOVA analysis was used, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. )

[0024] Figure 4 Exposure levels of 10-hydroxydecenoic acid in rats after oral administration; A: Exposure levels of 10-hydroxydecenoic acid in plasma; B: Exposure levels of 10-hydroxydecenoic acid in hippocampus; C: Exposure levels of 10-hydroxydecenoic acid in striatum. 10-hydroxydecenoic acid was dispersed in 0.5% CMC-Na solution to form a suspension (H), or meglumine was added to solubilize and prepare a true solution (R). The dosage of 10-hydroxydecenoic acid was 120 mg / kg. One-way ANOVA analysis was used, *p<0.05, **p<0.01,

[0025] ***p<0.001.

[0026] Figure 5 Comparison of dissolution of 10-hydroxydecenoic acid tablets containing meglumine and ordinary tablets; A: dissolution in artificial gastric juice; B: dissolution in artificial intestinal juice.

[0027] Figure 6 Comparison of the solubility of 10-hydroxydecenoic acid dispersible tablets and ordinary tablets in artificial gastric juice; A: dissolution of ordinary tablets and dispersible tablets without meglumine; B: dissolution of ordinary tablets and dispersible tablets containing meglumine.

[0028] Figure 7 Effects of oral administration of 10-hydroxydecenoic acid solution on neurotransmitters in major brain tissues; A: striatal dopamine level; B: hippocampal dopamine level; C: striatal acetylcholine level; D: cortical acetylcholine level. 10-hydroxydecenoic acid was dispersed in 0.5% CMC-Na solution to form a suspension, or added with meglumine to form a solution and then administered. The dosage of 10-hydroxydecenoic acid was 120 mg / kg, and one-way ANOVA analysis was used, *p<0.05. DETAILED DESCRIPTION

[0029] The following examples can enable those skilled in the art to more fully understand the present invention, but the present invention is not limited to the scope of the examples. The "appropriate amount" in the examples is a range routinely selected by those skilled in the art.

[0030] Example 1 Study on the solubilization formula of 10-hydroxydecenoic acid liquid preparation

[0031] 10-Hydroxydecenoic acid is poorly soluble in water. A pharmaceutical method was used to add solubilizing means such as cosolvents, and a prescription study was conducted according to the dosage in Table 1. The EP tubes were divided into approximately 1.5 ml tubes, and were placed at room temperature and refrigerated at 4°C for 3 days. The solution state was observed. It was found that all prescriptions (prescriptions 1, 2, 3, 5, and 6) that did not contain meglumine became turbid or had a small amount of undissolved precipitate after being placed at room temperature or refrigerated at 4°C for 3 days. Prescriptions 4, 8, and 9 were stable, clear, and transparent after being prepared, placed at room temperature for 3 days, and refrigerated at 4°C for 3 days (Table 1).

[0032] Table 1 Study on the solubilization formula of 10-hydroxydecenoic acid liquid preparation

[0033]

[0034] Example 210-Hydroxydecenoic acid injection preparation

[0035] Based on the research results of prescriptions 4 and 9 in Example 1, 10-hydroxydecenoic acid injection was prepared with meglumine as a cosolvent, sodium thiosulfate as a stabilizer, and purified water as a dispersing solvent, with specifications ①-④ being 15, 30, 60, and 120 mg / 5 mL, respectively. The prescription is as follows:

[0036]

[0037] Preparation process: Weigh 1.5g / 2.0g / 3.0g / 4.0g of meglumine and 1.0g of sodium thiosulfate respectively, add to 50mL of purified water to dissolve, then weigh 0.3g / 0.6g / 1.2g / 2.4g of 10-hydroxydecenoic acid respectively, dissolve in the above solution, add purified water to 100mL, add 0.1% activated carbon, keep boiling for 10 minutes, cool to 45-50℃, filter with 0.45 micron microporous membrane, and package. The unit preparation is 5mL, containing 15, 30, 60 or 120mg of 10-hydroxydecenoic acid respectively. Sterilize with circulating steam at 100℃ for 20 minutes.

[0038] Example 310-Hydroxydecenoic acid oral solution preparation

[0039] Based on the research results of prescription 9 in Example 1, 10-hydroxydecenoic acid oral solution was prepared with meglumine as a cosolvent, sodium thiosulfate as a stabilizer, and purified water as a dispersing solvent, with specifications ①-④ being 15, 30, 60, and 120 mg / 5 mL, respectively. The prescription is as follows:

[0040]

[0041] Preparation process: Weigh 1.5g / 2.0g / 3.0g / 4.0g of meglumine and 1.0g of sodium thiosulfate respectively, add them into 50mL of purified water to dissolve, then weigh 0.3g / 0.6g / 1.2g / 2.4g of 10-hydroxydecenoic acid respectively, dissolve them in the above solutions, add purified water to 100mL, shake and mix, filter through 0.8-micron microporous membrane, and package. The unit preparation is 5mL, containing 15, 30, 60 or 120mg of 10-hydroxydecenoic acid respectively.

[0042] Example 4 Preparation of 10-hydroxydecenoic acid dispersible tablets containing meglumine

[0043] Preparation of 10-hydroxydecenoic acid dispersible tablets containing meglumine, specifications ①-④ are 30, 60, 120, and 240 mg / tablet, respectively. The prescription is as follows:

[0044]

[0045] Preparation process: 10-hydroxydecenoic acid, meglumine, microcrystalline cellulose, compressible starch, sodium thiosulfate, sodium carboxymethyl starch are weighed according to the above prescription, and they are sieved through 80 meshes respectively and mixed evenly; 30% ethanol solution is used to make soft material, granulated through 20 meshes, dried at 60℃ for 2 hours, micro powder silica gel (sieved through 120 meshes) is added, mixed evenly, and tableted. 100 tablets are prepared, containing 30, 60, 120 or 240 mg of 10-hydroxydecenoic acid respectively.

[0046] Example 5 Preparation of common tablets of 10-hydroxydecenoic acid containing meglumine

[0047] Preparation of meglumine-containing 10-hydroxydecenoic acid tablets, specifications ①-④ are 30, 60, 120, and 240 mg / tablet, respectively. The prescription is as follows:

[0048]

[0049] Preparation process: According to the above prescription, 10-hydroxydecenoic acid, corn starch, microcrystalline cellulose, meglumine, and thiosulfuric acid are weighed respectively, passed through an 80-mesh sieve, and mixed evenly; 3g of povidone is taken separately, dissolved in about 7 ml of 1% hydroxypropylcellulose solution, and soft material is prepared by conventional methods, passed through a 20-mesh sieve for granulation, and dried at 60°C for 2 hours, and micro powder silica gel (passed through a 120-mesh sieve) is added, mixed evenly, and tableted. 100 tablets are prepared, containing 30, 60, 120, or 240 mg of 10-hydroxydecenoic acid respectively.

[0050] Comparative Example 1 Preparation of 10-hydroxydecenoic acid oral suspension

[0051] Prepare 10-hydroxydecenoic acid suspension, specifications ①-④ are 15, 30, 60, 120 mg / 5 mL respectively. The prescription is as follows:

[0052] 10-Hydroxydecenoic acid 0.3g / 0.6g / 1.2g / 2.4g

[0053] Sodium carboxymethyl cellulose 0.5g

[0054] Add distilled water to 100 mL

[0055] Preparation process: Weigh 0.3g / 0.6g / 1.2g / 2.4g of 10-hydroxydecenoic acid respectively and pass through a 60-mesh sieve; take 0.5g of sodium carboxymethyl cellulose (CMC-Na) and pass through an 80-mesh sieve. Disperse and dissolve sodium carboxymethyl cellulose in 100mL of distilled water, add sodium thiosulfate, disperse and suspend 10-hydroxydecenoic acid in 0.5% sodium carboxymethyl cellulose aqueous solution, shake and suspend evenly, and the unit preparation is 5mL, containing 15, 30, 60 or 120mg of 10-hydroxydecenoic acid respectively.

[0056] Comparative Example 2 Preparation of 10-Hydroxydecenoic Acid Dispersible Tablets

[0057] 10-Hydroxydecenoic acid dispersible tablets were prepared, with specifications ①-④ of 30, 60, 120, and 240 mg / tablet, respectively. The prescription is as follows:

[0058]

[0059] Preparation process: According to the above prescription, 10-hydroxydecenoic acid, compressible starch, microcrystalline cellulose, sodium carboxymethyl starch are weighed respectively, passed through an 80-mesh sieve, and mixed evenly; 3g of povidone and 1.0g of sodium thiosulfate are dissolved in about 7 ml of 30% ethanol solution, and soft materials are prepared by conventional methods, granulated through a 20-mesh sieve, dried at 60°C for 2 hours, and micro-powdered silica gel (passed through a 120-mesh sieve) is added, mixed evenly, and tableted. 100 tablets are prepared, containing 30, 60, 120 or 240 mg of 10-hydroxydecenoic acid respectively.

[0060] Comparative Example 3 Preparation of 10-hydroxydecenoic acid common tablets

[0061] 10-Hydroxydecenoic acid tablets were prepared, with specifications ①-④ being 30, 60, 120, and 240 mg / tablet, respectively. The prescription is as follows:

[0062]

[0063]

[0064] Preparation process: According to the above prescription, 10-hydroxydecenoic acid, corn starch and microcrystalline cellulose are weighed respectively, passed through an 80-mesh sieve respectively, and mixed evenly; 3g of povidone and 1.0g of sodium thiosulfate are separately taken, dissolved in about 9 ml of 1% hydroxypropylcellulose solution, and soft material is prepared by conventional methods, passed through a 20-mesh sieve for granulation, and dried at 60°C for 2 hours, and micro-powdered silica gel (passed through a 120-mesh sieve) is added, mixed evenly, and tableted. 100 tablets are prepared, containing 30, 60, 120 or 240 mg of 10-hydroxydecenoic acid respectively.

[0065] Test Example 1 Study on the efficacy of 10-hydroxydecenoic acid solution on AD model mice induced by D-galactose and aluminum chloride

[0066] Animal species selection: KM mice (male, 4 weeks old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., weighing 24-32 g) were used and adaptively raised for one week under a standard breeding environment (free food and water, alternating day and night, 12 hours each).

[0067] Establishment of AlCl3-induced AD mouse model: After KM mice were adaptively cultured for seven days, D-galactose (150 mg / kg) was subcutaneously injected and AlCl3 solution (200 mg / kg) was orally administered for 30 consecutive days to establish the AD mouse model. Blank mice were given the same volume of saline ( Figure 1 A). D-galactose is reducing, causing oxidative stress and inflammation, which in turn leads to neurosenescence and cognitive impairment; high concentrations of aluminum in brain tissue induce neuronal degeneration and necrosis, and spatial learning and memory abilities are impaired. The combined use of D-galactose and aluminum trichloride to construct a subacute aging model can cause neuronal degeneration and cognitive decline in experimental animals, thereby simulating AD pathological characteristics. One month after modeling, the mice were randomly divided into model group, low-dose group, high-dose group, and positive drug control group for experiments.

[0068] Administration method: According to Comparative Example 1, AD model mice were gavaged with 60 mg / kg or 120 mg / kg of 10-hydroxydecenoic acid suspension (low-dose group and high-dose group), the positive drug control group was given 5 mg / kg of donepezil, and the blank control group and model group were given an equal volume of 0.5% CMC-Na solution.

[0069] Morris water maze experiment: In order to explore the effect of 10-hydroxydecenoic acid on the motor behavior of mice, the Morris water maze was used to evaluate the learning and memory ability of experimental animals. Starting from the third day after administration, water maze positioning and navigation training was carried out. The circular pool is 45 cm high and 60 cm in radius, which is divided into 4 quadrants. The platform (radius 5 cm) is placed in the fourth quadrant, the water level is slightly higher than the platform by 1 cm, and the water temperature is maintained at 24 ° C. Pay attention to avoid light and keep quiet during the experiment. During the training period, the mouse is placed in the pool with its back to the platform and facing the pool wall from any of the four starting points on the pool wall. The swimming time is set to 60s. If the mouse can find the platform and stay within 60s, the collection is automatically ended, and the mouse's swimming trajectory and the time to find the platform (escape latency) are recorded. If the mouse still does not find the platform after more than 60s, the experimenter will guide it to the platform and let it stay on the platform and remember it. The four training sessions will put the mouse into the water from four different starting points, and the average value of the mouse's four training latencies will be used as the mouse's learning performance for the day. The training lasts for five days. After the training period, the original platform was removed, the guidance was stopped, and the mice were subjected to a spatial exploration test. The number of times the mice crossed the platform and the swimming path within 60 seconds were recorded.

[0070] The experimental results showed that after five days of training, compared with the blank mice, the model mice took longer to find the platform and had chaotic swimming trajectories, indicating that the combined modeling of D-galactose and aluminum chloride can lead to cognitive impairment and decreased learning and memory in KM mice. Compared with the model group mice, the escape latency of the mice administered with donepezil and the two groups of mice administered with 10-hydroxydecenoic acid was significantly reduced, and the degree of chaotic swimming trajectories was significantly reduced. The high-dose group was slightly more effective than the low-dose group ( Figure 1 B, 1H). The space exploration experiment on the sixth day showed that compared with the model group mice, the blank control, positive drug control and 10-hydroxydecenoic acid-treated mice all showed an increase in the number of platform area crossings, the number of times entering the target quadrant, and the increase in the movement time and distance in the target quadrant ( Figure 1 CF, 1I). Compared with the low-dose group and the positive drug donepezil group, the high-dose group showed more significant behavioral improvements, that is, the high-dose 10-hydroxydecenoic acid had a more significant effect. These results show that, consistent with the positive drug donepezil, 10-hydroxydecenoic acid can improve cognitive impairment induced by D-galactose and aluminum chloride, improve the learning and spatial memory ability of experimental mice, and the efficacy is dose-dependent.

[0071] Y-maze experiment: The Y-maze experiment is used to evaluate the spatial memory and cognitive ability of experimental mice. Alternation behavior utilizes the experimental animals' nature of exploring new environments. During the search process, the experimental animals need to remember the direction they explored last time to avoid repeated entry. Therefore, the Y-maze experiment can effectively measure the spatial memory ability of the experiment. Place the experimental mouse at the end of any arm and let it explore freely in the Y-maze for 5 minutes, and record the total number of times the mouse enters each arm. All four feet of the mouse enter the arm once, and alternation refers to entering three different arms of the maze in sequence (123, 132, 312, etc. are all possible). The maximum number of turns refers to the total number of arms entered - 2, and the alternation percentage = total number of turns / maximum number of turns × 100%.

[0072] The experimental results showed that the alternation percentage of the modeling group mice decreased, indicating that D-galactose and aluminum chloride can induce cognitive impairment and memory loss in KM mice. The alternation percentage of the two groups of mice administered with 10-hydroxydecenoic acid was significantly increased, which alleviated their spatial memory cognitive impairment and enhanced their desire to explore. The significance of the anti-AD efficacy of 10-hydroxydecenoic acid was better than that of the positive drug donepezil group: among the six indicators, compared with the model group, high-dose 10-hydroxydecenoic acid significantly improved 5 indicators (**, p<0.01) and significantly improved 1 indicator (*, p<0.05); while the positive drug only significantly changed 1 indicator (**, p<0.01), significantly changed 2 indicators (*, p<0.05), and did not significantly change 3 indicators. It shows that 10-hydroxydecenoic acid can improve cognitive impairment and memory impairment induced by D-galactose and aluminum chloride.

[0073] In summary, the administration of 10-hydroxydecenoic acid suspension can significantly improve the cognitive impairment and memory learning ability of AD model mice induced by D-galactose and aluminum chloride, and the efficacy is dose-dependent. This provides a basis for efficacy and dosage guidance for subsequent studies.

[0074] Test Example 2: Study on the efficacy of 10-hydroxydecenoic acid solution and suspension on rats with AD induced by ibotenic acid

[0075] Animal species selection: SD rats (male, 6-7 weeks old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., weighing 220±20g) were used and adaptively raised for one week under a standard breeding environment (free diet and drinking water, alternating day and night, 12 hours each).

[0076] Establishment of animal model: Ibotenic acid (IBO) is a neurotoxin. Intracranial injection of IBO damages the Meynert basal nucleus and its cholinergic nervous system, causing neuronal damage and cognitive impairment in the animal model. After seven days of adaptive culture of SD rats, IBO was injected into the striatum using a brain stereotaxic instrument. After intraperitoneal anesthesia, the experimental animals were fixed on the brain stereotaxic instrument, the head skin was disinfected and cut open, the subcutaneous tissue was separated, and the skull was exposed. Referring to the Paxinos rat brain stereotaxic atlas (coordinates: 1.0mm behind the anterior fontanelle, 2.7mm beside the midline, 7.0mm deep), the skull was drilled at the location with a skull drill, and 2μL of IBO solution (dissolved in sterile saline, concentration 1.25μg / μL) was slowly injected on each side. The control group was injected with the same volume of sterile saline. One week after modeling, the rats were randomly divided into model group, true solution group, and suspension group for experiment (see Figure 2 A).

[0077] Administration method: 120 mg / kg of 10-hydroxydecenoic acid (true solution group and suspension group) was administered to SD model rats by gavage according to Example 3 and Comparative Example 1, and an equal volume of 0.5% CMC-Na solution was administered to the control group and the model group.

[0078] Morris water maze test: In order to evaluate the effect of 10-hydroxydecenoic acid on the motor behavior of rats, Morris water maze was used to evaluate the learning and memory ability of experimental rats. Starting from the third day after administration, water maze positioning navigation training was carried out. The circular pool was 45 cm high and 80 cm in radius, and it was divided into 4 quadrants. The rest of the operations were consistent with test example 1.

[0079] The experimental results showed that after five days of training, compared with the blank rats, the IBO-induced model rats took longer to find the platform and had a chaotic swimming trajectory, indicating that IBO can cause cognitive impairment and decreased learning and memory in rats. Compared with the model group, the escape latency of the two groups of rats treated with the drug was significantly reduced, and the degree of chaotic swimming trajectory was significantly reduced. The statistical significance of the difference showed that the true solution group had better efficacy, indicating that 10-hydroxydecenoic acid can improve the cognitive impairment of model rats ( Figure 2 B, 2H). The space exploration experiment on the sixth day showed that compared with the model group, the blank control and 10-hydroxydecenoic acid-treated rats showed an increase in the number of platform area crossings, the number of times entering the target quadrant, and the increase in the target quadrant movement time and distance ( Figure 2 CF, 2I), and the statistical difference showed that the efficacy of the true solution group was better than that of the suspension group. This showed that 10-hydroxydecenoic acid could improve the cognitive impairment of IBO and enhance the learning and spatial memory ability of experimental rats, and the efficacy of the true solution group was better than that of the suspension group, that is, meglumine as a cosolvent was more conducive to the efficacy of the drug.

[0080] Y-maze test: The experimental animals were placed at the end of any arm and allowed to freely explore the Y-maze for 8 minutes. The rest of the operations were the same as in Test Example 1. The experimental results showed that the rats in the IBO modeling group showed a decrease in the alternation percentage, indicating that IBO injection into the basal ganglia brain region can induce cognitive impairment and memory loss in SD rats. The alternation percentage of the two groups of rats administered with 10-hydroxydecenoic acid was significantly increased, which alleviated their spatial memory cognitive impairment and enhanced their desire to explore. The statistical significance of the difference showed that the efficacy of the true solution group was significantly better than that of the suspension group, and was equivalent to that of the blank control group ( Figure 2 G). Based on the results of the six evaluation indicators, the analysis found that compared with the model group, the administration of the solution containing meglumine significantly improved three of the indicators (**, p<0.01), significantly improved the other three indicators (*, p<0.05), and no statistically significant changes were found; while in the group using CMC-Na as a suspension, only two indicators (*, p<0.05) showed statistically significant improvements (*, p<0.05), and the other four indicators showed no significant statistical differences. That is, the addition of the excipient meglumine for solubilization had an unexpected synergistic effect. This shows that 10-hydroxydecenoic acid can improve IBO-induced cognitive impairment and memory impairment, and meglumine as a cosolvent is more conducive to the efficacy of the drug.

[0081] In summary, the administration of 10-hydroxydecenoic acid can significantly improve the cognitive impairment and memory learning ability of IBO-induced AD model rats, and the behavioral effect of the true solution group is better than that of the suspension group, indicating that meglumine in the oral solution is conducive to the better anti-AD efficacy of 10-hydroxydecenoic acid.

[0082] Test Example 310-Hydroxydecenoic Acid Solution and Suspension in Scopolamine-Induced AD Model Mice

[0083] Animal species selection: KM mice (male, 4 weeks old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., weighing 24-32 g) were used and adaptively raised for one week under a standard breeding environment (free food and water, alternating day and night, 12 hours each).

[0084] Establishment of animal model: After KM mice were adaptively cultured for seven days, scopolamine was intraperitoneally injected at a dose of 3 mg / kg for 14 consecutive days to establish an AD mouse model, and the blank mice were given the same volume of saline. Scopolamine can inhibit the binding of acetylcholine to its receptors, causing cholinergic system disorders, resulting in learning and memory disorders in experimental animals. Twelve days after modeling, the mice were randomly divided into model group, true solution group, and suspension group for experiments (see Figure 3 A).

[0085] Administration method: AD model mice were gavaged with 120 mg / kg of 10-hydroxydecenoic acid (true solution group and suspension group) according to Example 3 and Comparative Example 1, and the control group and model group were given an equal volume of 0.5% CMC-Na solution.

[0086] Morris water maze test: The same method as in Test Example 1 was used to evaluate the learning and memory abilities of experimental mice. The experimental results showed that after five days of training, compared with blank mice, the model mice induced by scopolamine took longer to find the platform and had chaotic swimming trajectories, indicating that scopolamine can cause cognitive impairment and decreased learning and memory in KM mice. Compared with the model group mice, the escape latency of the two groups of mice treated with the drug was significantly reduced, and the degree of chaotic swimming trajectories was significantly reduced, indicating that 10-hydroxydecenoic acid can improve the cognitive impairment of model mice ( Figure 3 B, 3H). The space exploration experiment on the sixth day showed that compared with the model group mice, the blank control and 10-hydroxydecenoic acid-treated mice showed an increase in the number of platform area crossings and the increase in target quadrant movement time and distance, and the efficacy of the true solution group was better than that of the suspension group ( Figure 3 C, 3E, 3F, 3I). In addition, the number of times mice in the drug-treated group entered the target quadrant increased slightly, but no significant difference was observed ( Figure 3 D). These results indicate that 10-hydroxydecenoic acid can improve scopolamine-induced cognitive impairment and enhance the learning and spatial memory abilities of experimental mice. The statistical significance of the difference shows that the efficacy of the true solution group is superior to that of the suspension group, that is, meglumine as a cosolvent is conducive to the efficacy of the drug.

[0087] Y-maze test: The spatial memory and cognitive ability of experimental mice were evaluated using the same method as in Test Example 1. The experimental results showed that the mice in the modeling group showed a decrease in the alternation percentage, indicating that intraperitoneal injection of scopolamine can induce cognitive impairment and memory loss in KM mice. The alternation percentage of the two groups of mice administered with 10-hydroxydecenoic acid was significantly improved, which alleviated their spatial memory cognitive impairment and enhanced their desire to explore. The statistical significance of the difference showed that the efficacy of the true solution group was significantly better than that of the suspension group, and was equivalent to that of the blank control group ( Figure 3G). Based on the results of the six evaluation indicators, the analysis found that compared with the model group, the administration of the solution containing meglumine significantly improved two of the indicators (**, p<0.01), significantly improved three indicators (*, p<0.05), and the other one had no statistical difference after administration; while in the group using CMC-Na as a suspension, only one indicator showed a very significant (**, p<0.01) statistical difference, the improvement of one indicator had a significant statistical difference (*, p<0.05), and the other four indicators had no significant statistical difference. That is, the addition of the excipient meglumine for solubilization had an unexpected synergistic effect. It shows that 10-hydroxydecenoic acid can improve scopolamine-induced cognitive impairment and memory impairment, and meglumine as a cosolvent is more conducive to the efficacy of the drug.

[0088] In summary, the administration of 10-hydroxydecenoic acid can significantly improve the cognitive impairment and memory learning ability of scopolamine-induced AD model mice, and the behavioral improvement effect of mice in the true solution group after administration is better than that in the suspension group, indicating that meglumine in the oral solution is conducive to the better anti-AD efficacy of 10-hydroxydecenoic acid.

[0089] Test Example 4 Study on the Effect of Meglumine on Drug Exposure Levels of 10-Hydroxydecenoic Acid in Rat Plasma and Tissues

[0090] Animals and administration method: 16 SD rats aged 6-7 weeks (weight 200 ± 20g), half male and half female, were randomly divided into 2 groups according to body weight, 8 rats in each group (half male and half female). Free food and water were allowed to adapt to the environment for one week before administration. Fasting for 12 hours before the experiment, but water was not allowed. Oral solution of Example 3 and oral suspension of Comparative Example 1 were respectively used for oral administration (120mg / kg). Blood samples of 200 μL were collected at 2, 5, 10, 20, 40, 60, 120, 240, and 360 minutes after administration, and sodium heparin EP tubes were added. The plasma supernatant was separated and stored in a -80°C refrigerator for standby use. Animals were grouped and administered with the above method. Rats were anesthetized and killed at 10 and 40 minutes after administration, respectively, and the hippocampus, cortex, and striatum were collected. The tissues were washed with ice physiological saline solution, and after being dried with absorbent paper, they were stored in a -80°C refrigerator for standby use.

[0091] Quantitative determination method of 10-hydroxydecenoic acid: LC-MS / MS analysis was performed using a Shimadzu high performance liquid chromatograph (including a SIL-20ACXR constant temperature automatic sampler, a CTO-20A column oven, and a DGU-20A3 online vacuum degasser), connected in series with an American AB mass spectrometer system (API 5500), an electrospray ion source (ESI), and an Analyst 1.6.1 workstation.

[0092] Plasma and tissue samples were treated with organic solvent protein precipitation and centrifuged twice (4℃, 18000rpm centrifugation for 5min), and 5μL of the supernatant was injected. The chromatographic column was Agilent ZORBAX Eclipse Plus C18 (2.1×50mm, 3.5μm), the column temperature was 40℃, and the mobile phase was methanol-0.02% ammonium formate aqueous solution. The gradient elution method was adopted with a flow rate of 0.3mL / min. In the electrospray ionization (ESI) mode, the ion spray voltage was -4500V; auxiliary gas 1 and 2 were both nitrogen: 50Arb, 55Arb; auxiliary gas temperature was 500℃; curtain gas was 30Arb; collision gas: 10Arb; inlet voltage EP: -10V; outlet voltage CXP: -5V. Multiple reaction monitoring (MRM) mode was used to detect negative ions. The ion pair of 10-hydroxydecenoic acid detection was 185.00→139.00. CE: -22eV; DP: -70V were set. The internal standard was chlorzoxazone. In the ESI negative ion mode, the ion pair was 168.00→132.00. In addition, a series of standard solutions were prepared and the sample determination method was used to draw the working curve and calculate the concentration level of 10-hydroxydecenoic acid in plasma and tissue samples.

[0093] Results: After the administration of solution and suspension, the drug concentration in plasma increased rapidly in a short period of time (10 minutes after administration), and then decreased significantly ( Figure 4 A), indicating that 10-hydroxydecenoic acid can be rapidly absorbed in the gastrointestinal tract. In addition, the exposure level of 10-hydroxydecenoic acid in plasma after administration in the form of true solution was significantly higher than that after administration in the form of suspension, indicating that meglumine solubilization is beneficial to increase the exposure level of 10-hydroxydecenoic acid in the circulatory system.

[0094] The drug concentration levels in the central hippocampus and striatum increased within a short period of time after administration (10 minutes after administration), and then decreased significantly, indicating that 10-hydroxydecenoic acid easily enters the central tissue. In addition, after 10-hydroxydecenoic acid was administered in the form of a true solution, the overall exposure level in the hippocampus and striatum was higher than that of the suspension ( Figure 4 BC), suggesting that meglumine solubilization is beneficial to increase the exposure level of 10-hydroxydecenoic acid in the central nervous system, especially in tissues such as the hippocampus and striatum.

[0095] Conclusion: After oral administration of 10-hydroxydecenoic acid, the exposure level in the blood and brain tissue (hippocampus, cortex, and striatum) of SD rats was high. Meglumine can significantly increase the exposure level of 10-hydroxydecenoic acid in plasma, hippocampus, and striatum, suggesting that it is beneficial to the anti-AD effect.

[0096] Test Example 5 Dissolution of 10-Hydroxydecenoic Acid Dispersible Tablets in Simulated Artificial Gastric / Intestinal Fluids in Vitro

[0097] 1. Solubility in artificial gastric juice:

[0098] The simulated artificial gastric juice was prepared by the paddle method according to the pharmacopoeia method, and the pH was adjusted to about 1.5. 900 ml of artificial gastric juice was added to each dissolution cup. After the temperature reached and equilibrated at 37°C, 1 tablet of each of the 10-hydroxydecenoic acid dispersible tablets without meglumine in Comparative Example 2 and the 10-hydroxydecenoic acid dispersible tablets containing meglumine in Example 4 were placed in six dissolution cups, and the speed was adjusted to 80 rpm. 1 ml of filtrate was taken at 5, 15, 30, 45, and 60 minutes, and the LC-MS / MS method for determining the acidity of 10-hydroxydecenoic acid in the above-mentioned test example 4 was used to calculate the dissolved amount of 10-hydroxydecenoic acid, and the dissolved percentage was calculated by comparing with the labeled amount, and the dissolution curve was drawn to compare the dissolution difference of the two tablets.

[0099] Results: Both tablets disintegrated quickly in artificial gastric juice, and the solution became turbid. The test results showed that 10-hydroxydecenoic acid dissolved slowly in artificial gastric juice, and the solubility increased with time. At 60 minutes, the average solubility of 10-hydroxydecenoic acid dispersible tablets without meglumine was 65.4%, and the average solubility of 10-hydroxydecenoic acid dispersible tablets with meglumine was 79.9% ( Figure 5 A).

[0100] Conclusion: Based on the dissolution rate and 60-minute maximum dissolution of the two tablets in artificial gastric juice, the analysis found that the tablets containing meglumine were significantly faster and / or higher than the ordinary tablets without meglumine in terms of both dissolution rate and 60-minute maximum dissolution. That is, the addition of excipient meglumine significantly increased the dissolution of 10-hydroxydecenoic acid in artificial gastric juice, and an unexpected effect of increasing dissolution appeared. It has obvious pharmaceutical advantages.

[0101] The dissolution of 10-hydroxydecenoic acid in artificial gastric juice was relatively slow, and meglumine significantly promoted the dissolution of 10-hydroxydecenoic acid in artificial gastric juice.

[0102] 2. Dissolution in artificial intestinal fluid:

[0103] The simulated artificial intestinal fluid was prepared by the slurry method according to the pharmacopoeia method, and the pH was adjusted to about 6.8. 900 ml of artificial intestinal fluid was added to the dissolution cups respectively. After the temperature reached and equilibrated at 37°C, 1 tablet of 10-hydroxydecenoic acid dispersible tablets without meglumine in Comparative Example 2 and 1 tablet of 10-hydroxydecenoic acid dispersible tablets containing meglumine in Example 4 were placed in six dissolution cups respectively, and the speed was adjusted to 80 rpm. 1 ml of filtrate was taken at 5, 15, 30, 45, and 60 minutes respectively. After dilution, the acidity of 10-hydroxydecenoic acid was determined by LC / MS method, the amount of 10-hydroxydecenoic acid dissolved was calculated, and the dissolution percentage was calculated by comparing with the labeled amount. The dissolution curve was drawn to compare the dissolution difference of the two tablets.

[0104] Results: Both tablets disintegrated quickly in artificial intestinal fluid, and the solution became turbid. The test results showed that 10-hydroxydecenoic acid dissolved quickly in artificial intestinal fluid, and the solubility increased with time. At 60 minutes, the average solubility of 10-hydroxydecenoic acid dispersible tablets without meglumine was 90.5%, and the average solubility of 10-hydroxydecenoic acid dispersible tablets with meglumine was 99.9% ( Figure 5 B).

[0105] The dissolution rate and 60-minute maximum dissolution rate of the two tablets in artificial intestinal fluid were analyzed and found that the tablet containing meglumine was significantly faster and / or higher than the ordinary tablet without meglumine in terms of both dissolution rate and maximum dissolution rate in 60 minutes. That is, the addition of excipient meglumine significantly increased the dissolution of 10-hydroxydecenoic acid in artificial intestinal fluid, and an unexpected effect of increasing dissolution rate appeared. It has obvious pharmaceutical advantages.

[0106] 3. Comparison of dissolution of ordinary tablets and dispersible tablets in artificial gastric juice:

[0107] The same method as the artificial gastric juice in the above 1 was used to place the 10-hydroxydecenoic acid dispersible tablets without meglumine in Comparative Example 2 and the 10-hydroxydecenoic acid ordinary tablets without meglumine in Comparative Example 3 in six dissolution cups, respectively, and the rotation speed was adjusted to 80 rpm. 1 ml of the filtrate was taken at 5, 15, 30, 45, and 60 minutes, and the LC-MS / MS method for determining the acidity of 10-hydroxydecenoic acid in the above Test Example 4 was used to calculate the dissolved amount of 10-hydroxydecenoic acid, and the dissolved percentage was calculated by comparing with the labeled amount, and the dissolution curve was drawn to compare the dissolution difference of the two tablets.

[0108] According to the same method as above, the 10-hydroxydecenoic acid dispersible tablets containing meglumine in Example 4 and the 10-hydroxydecenoic acid ordinary tablets containing meglumine in Example 5 were placed in six dissolution cups respectively to compare the dissolution rates.

[0109] Results: The dispersible tablets without meglumine disintegrated and dissolved faster than the ordinary tablets in artificial gastric juice. The average dissolution rate of the ordinary tablets was 34.9% and the average dissolution rate of the dispersible tablets was 65.4% ( Figure 6 A). Dispersible tablets containing meglumine disintegrate and dissolve faster than ordinary tablets in artificial gastric juice. At 60 minutes, the average dissolution rate of ordinary tablets is 44.8%, and the average dissolution rate of dispersible tablets is 79.9% ( Figure 6 B). The above results show that the 10-hydroxydecenoic acid dispersible tablets dissolve more rapidly in artificial gastric juice than its ordinary tablets, and meglumine can promote the dissolution of 10-hydroxydecenoic acid in artificial gastric juice.

[0110] The dissolution rate and 60-minute maximum dissolution rate of dispersible tablets and ordinary tablets were analyzed and found that regardless of whether meglumine was added to the preparation, the dissolution rate and 60-minute maximum dissolution rate of dispersible tablets were significantly faster than / or higher than ordinary tablets. That is, the addition of excipient meglumine significantly increased the dissolution of 10-hydroxydecenoic acid, and an unexpected effect of increasing dissolution rate appeared. It has obvious dosage form advantages.

[0111] Conclusion: 10-hydroxydecenoic acid dissolves faster in artificial intestinal fluid than in artificial gastric fluid. Making 10-hydroxydecenoic acid into dispersible tablets or adding meglumine as tablet excipients can accelerate the dissolution of 10-hydroxydecenoic acid, which is beneficial to its absorption in the gastrointestinal tract and its efficacy.

[0112] Test Example 6 Effect of 10-hydroxydecenoic acid on neurotransmitters in the brain of AD model rats

[0113] Animal species selection: SD rats (male, 6-7 weeks old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., weighing 220±20g) were used and adaptively raised for one week under a standard breeding environment (free diet and drinking water, alternating day and night, 12 hours each).

[0114] Establishment of animal model: Ibotenic acid (IBO) is a neurotoxin. Intracranial injection of IBO damages the nucleus basalis of Meynert and its cholinergic nervous system, causing neuronal damage and cognitive impairment in the animal model. After seven days of adaptive culture of SD rats, IBO was injected into the striatum using a brain stereotaxic instrument. After intraperitoneal anesthesia, the experimental animals were fixed on the brain stereotaxic instrument, the head skin was disinfected and cut open, the subcutaneous tissue was separated, and the skull was exposed. Referring to the Paxinos rat brain stereotaxic atlas (coordinates: 1.0mm behind the anterior fontanelle, 2.7mm beside the midline, 7.0mm deep), the skull was drilled at the location with a skull drill, and 2μL of IBO solution (dissolved in sterile saline, concentration 1.25μg / μL) was slowly injected on each side, and the control group was injected with the same volume of sterile saline.

[0115] Administration method: PD model mice were gavaged with 120 mg / kg of 10-hydroxydecenoic acid (true solution group and suspension group) according to Example 3 and Comparative Example 1, and the control group and model group were given an equal volume of 0.5% CMC-Na solution.

[0116] Sample collection: Brain tissue samples were collected one week after administration, and the neurotransmitters in the striatum, hippocampus, and cortex were determined using LC-MS / MS technology, and the DA and Ach levels in the rat central nervous system after administration of the true solution and suspension were compared.

[0117] Results: Compared with the control group, the DA levels in the striatum and hippocampus of IBO model rats were decreased, while 10-hydroxydecenoic acid could increase the DA levels in the striatum and hippocampus, and the true solution of 10-hydroxydecenoic acid containing meglumine was more effective ( Figure 7 AB); The Ach levels in the striatum and prefrontal cortex of IBO model rats were decreased, while 10-hydroxydecenoic acid could increase the Ach levels in the striatum and prefrontal cortex, and the true solution of 10-hydroxydecenoic acid containing meglumine was more effective ( Figure 7 CD);

[0118] The results of the four tests were analyzed and found that compared with the model group, the administration of the solution containing meglumine significantly improved the levels of two neurotransmitters in all three brain regions (4 indicators, *, p<0.05), and no statistically significant changes were found; while in the group using CMC-Na as a suspension, no significant statistical differences were found in the four indicators (including the levels of two neurotransmitters in three brain regions). That is, the addition of the excipient meglumine to solubilize has an unexpected effect of increasing the level of central nervous system neurotransmitters.

[0119] Conclusion: 10-hydroxydecenoic acid can increase the levels of DA and Ach in the hippocampus, striatum and cortex of IBO model rats. The 10-hydroxydecenoic acid solution containing meglumine has a more obvious effect on increasing neurotransmitters than the suspension, which is conducive to the better anti-AD effect of 10-hydroxydecenoic acid.

[0120] In summary, the present invention finds that oral administration of 10-hydroxydecenoic acid can significantly improve AD-like behaviors of various model mice; the preparation of dispersible tablets is conducive to the dissolution of 10-hydroxydecenoic acid; the addition of meglumine to the oral solid preparation accelerates the dissolution of 10-hydroxydecenoic acid and makes the anti-AD efficacy more obvious; meglumine can significantly increase the solubility of 10-hydroxydecenoic acid in aqueous solution and prepare an injection or a true solution; compared with the non-dissolving suspension administration method, the true solution administration makes the in vivo exposure level higher, the regulation of the neurotransmitters dopamine and acetylcholine is more obvious, and the anti-AD effect is better.

Claims

1. A preparation of 10-hydroxydecenoic acid for use in the preparation of a drug for treating Alzheimer's disease, wherein the preparation is selected from ordinary tablets, dispersible tablets, oral solutions or injections.

2. The preparation of 10-hydroxydecenoic acid according to claim 1, characterized in that The preparation is selected from injections and comprises the following ingredients by weight: 0.3-2.4 parts of 10-hydroxydecenoic acid, 1 part of sodium thiosulfate, 1.5-4.0 parts of meglumine and purified water.

3. The preparation of 10-hydroxydecenoic acid according to claim 2, characterized in that The unit preparation of 10-hydroxydecenoic acid injection is 5 mL, containing 10 to 240 mg of 10-hydroxydecenoic acid; preferably, the unit preparation of 10-hydroxydecenoic acid injection is 5 mL, containing 60 mg to 120 mg of 10-hydroxydecenoic acid.

4. The preparation of 10-hydroxydecenoic acid according to claim 1, characterized in that The preparation is selected from oral solution, and comprises the following ingredients by weight: 0.3-2.4 parts of 10-hydroxydecenoic acid, 1 part of sodium thiosulfate, 1.5-4.0 parts of meglumine and purified water.

5. The preparation of 10-hydroxydecenoic acid according to claim 4, characterized in that The unit preparation of 10-hydroxydecenoic acid oral solution is 5 mL, containing 10-240 mg 10-hydroxydecenoic acid; preferably, the unit preparation of 10-hydroxydecenoic acid oral solution is 5 mL, containing 60 mg-120 mg 10-hydroxydecenoic acid.

6. The preparation of 10-hydroxydecenoic acid according to claim 1, characterized in that The preparation is selected from dispersible tablets and includes the following ingredients by weight: 3 to 24 parts of 10-hydroxydecenoic acid, 10 to 25 parts of compressible starch, 10 to 12 parts of microcrystalline cellulose, 8 to 12 parts of sodium carboxymethyl starch, 10 to 30 parts of meglumine, 2 parts of sodium thiosulfate, and 0.6 parts of micro-powdered silica gel.

7. The preparation of 10-hydroxydecenoic acid according to claim 6, characterized in that Each 10-hydroxydecenoic acid dispersible tablet contains 10 mg to 360 mg of 10-hydroxydecenoic acid; more preferably, each 10-hydroxydecenoic acid dispersible tablet contains 60 mg to 120 mg of 10-hydroxydecenoic acid.

8. The preparation of 10-hydroxydecenoic acid according to claim 1, characterized in that The preparation is selected from common tablets and comprises the following ingredients by weight: 3-24 parts of 10-hydroxydecenoic acid, 10-25 parts of corn starch, 10-12 parts of microcrystalline cellulose, 3 parts of povidone, 1 part of sodium thiosulfate, 10-30 parts of meglumine and 0.5 parts of micro powder silica gel.

9. The preparation of 10-hydroxydecenoic acid according to claim 8, characterized in that Each ordinary tablet of 10-hydroxydecenoic acid contains 10 mg to 360 mg of 10-hydroxydecenoic acid; preferably, each ordinary tablet of 10-hydroxydecenoic acid contains 60 mg to 120 mg of 10-hydroxydecenoic acid.

10. Use of the preparation of 10-hydroxydecenoic acid according to claims 1 to 9 for preparing a drug for treating or preventing Alzheimer's disease.

Citation Information

Cited By

  • Application of E-10-hydroxy-2-decenoic acid in treatment of Alzheimer's disease

    CN117159530A

  • Application of 4-isopropylphenyl acetyl piperazine in preparation of anti-Alzheimer disease drugs

    CN119745886A